Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Medical University of South Carolina
mi
from
Charleston, SC
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Seattle Children's Hospital
mi
from
Seattle, WA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  9/6/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 9/6/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  9/6/2017
Lucile Packard Children's Hospital at Stanford University Medical Center
mi
from
Palo Alto, CA
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 9/6/2017
Lucile Packard Children's Hospital at Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  9/6/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 9/6/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  9/6/2017
University of Chicago Comer Children's Hospital
mi
from
Chicago, IL
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 9/6/2017
University of Chicago Comer Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  9/6/2017
C.S. Mott Children's Hospital at University of Michigan Medical Center
mi
from
Ann Arbor, MI
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 9/6/2017
C.S. Mott Children's Hospital at University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  9/6/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 9/6/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  9/6/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 9/6/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  9/6/2017
Texas Children's Hospital
mi
from
Houston, TX
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 9/6/2017
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  9/12/2017
Dana Farber Cancer Institute SC (1)
mi
from
Boston, MA
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 9/12/2017
Dana Farber Cancer Institute SC (1)
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  9/12/2017
University of Texas/MD Anderson Cancer Center MD Anderson DeGrout
mi
from
Houston, TX
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 9/12/2017
University of Texas/MD Anderson Cancer Center MD Anderson DeGrout
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  9/12/2017
Highlands Oncology Group Highlands Oncology
mi
from
Fayetteville, AR
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 9/12/2017
Highlands Oncology Group Highlands Oncology
mi
from
Fayetteville, AR
Click here to add this to my saved trials
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  9/12/2017
Novartis Investigative Site
mi
from
Melbourne,
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 9/12/2017
Novartis Investigative Site
mi
from
Melbourne,
Click here to add this to my saved trials
A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
Status: Enrolling
Updated:  9/12/2017
Johns Hopkins University
mi
from
Baltimore, MD
A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
Status: Enrolling
Updated: 9/12/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas
Status: Enrolling
Updated:  9/15/2017
Emory University
mi
from
Atlanta, GA
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas
Status: Enrolling
Updated: 9/15/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas
Status: Enrolling
Updated:  9/15/2017
Johns Hopkins University
mi
from
Baltimore, MD
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas
Status: Enrolling
Updated: 9/15/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas
Status: Enrolling
Updated:  9/15/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas
Status: Enrolling
Updated: 9/15/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas
Status: Enrolling
Updated:  9/15/2017
Wake Forest University
mi
from
Winston-Salem, NC
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas
Status: Enrolling
Updated: 9/15/2017
Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas
Status: Enrolling
Updated:  9/15/2017
Cleveland Clinic
mi
from
Cleveland, OH
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas
Status: Enrolling
Updated: 9/15/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated:  9/20/2017
Moores UC San Diego Cancer Center
mi
from
La Jolla, CA
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated: 9/20/2017
Moores UC San Diego Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated:  9/20/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated: 9/20/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated:  9/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated: 9/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated:  9/20/2017
Massachusetts General Hospital
mi
from
Boston, MA
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated: 9/20/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated:  9/20/2017
Norris Cotton Cancer Center
mi
from
Lebanon, NH
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated: 9/20/2017
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated:  9/20/2017
UPMC Cancer Center
mi
from
Pittsburgh, PA
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated: 9/20/2017
UPMC Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated:  9/20/2017
Univeristy of Texas Health Science Center San Antonio
mi
from
San Antonio, TX
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated: 9/20/2017
Univeristy of Texas Health Science Center San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated:  9/20/2017
Emily Couric Clinical Cancer Center
mi
from
Charlottesville, VA
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated: 9/20/2017
Emily Couric Clinical Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated:  9/20/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated: 9/20/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated:  9/20/2017
University of Washington Medical Center
mi
from
Seattle, WA
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated: 9/20/2017
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated:  9/20/2017
Northwestern University
mi
from
Chicago, IL
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated: 9/20/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated:  9/20/2017
Cleveland Clinic
mi
from
Cleveland, OH
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Status: Enrolling
Updated: 9/20/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of Arizona Cancer Center
mi
from
Tucson, AZ
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of California - LAC Medical Center
mi
from
Los Angeles, CA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of California - LAC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of Southern California, Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of Southern California, Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
UC Irvine Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
UC Irvine Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
GRU Cancer Center - Georgia Regents University
mi
from
Augusta, GA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
GRU Cancer Center - Georgia Regents University
mi
from
Augusta, GA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
National Cancer Institute
mi
from
Bethesda, MD
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
National Cancer Institute
mi
from
Bethesda, MD
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
Cancer and Hematology Centers of Western Michigan
mi
from
Grand Rapids, MI
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
Cancer and Hematology Centers of Western Michigan
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
The Long Islan Brain Tumor Center at Neurological Surgery P.C.
mi
from
Commack, NY
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
The Long Islan Brain Tumor Center at Neurological Surgery P.C.
mi
from
Commack, NY
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
Cleveland Clinic
mi
from
Cleveland, OH
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
Magee-Womens Hospital
mi
from
Pittsburgh, PA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
Magee-Womens Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
UPMC Cancer Center
mi
from
Pittsburgh, PA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
UPMC Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials